Printer Friendly

Effect of a Traditional Chinese Medicine Formula (Bu Shen Zhu Yun) on Mifepristone-Induced Abnormal Pituitary Gonadotropin Secretion in Rats.

Byline: Zhen-li Li, Hui-fang Zhou, Bo-ru Zhou, Bei Liu, Xiao-fei Jiang and Jian-ya Xu

Key words

Gonadotropin-releasing hormone receptor, Infertility, Luteal phase defect, Signaling pathway, Traditional Chinese medicine.

INTRODUCTION

Mifepristone is a progesterone antagonist with high efficacy; it has been widely used in clinics for suppressing endometrial hyperplasia and terminating early pregnancy (Cameron et al., 1996; Boggavarapu et al., 2016). Mifepristone can effectively block the action of progesterone on the endometrium after ovulation. This induces a presentation resembling luteal phase defect (LPD) in the endometrium and prevents the normal implantation of a fertilized egg, thereby producing a contraceptive effect. However, mifepristone has limited effect on the development of the endometrium during menstrual cycle and does not induce menstrual cycle disturbances in females; therefore, mifepristone remains widely used as a contraceptive drug. However, contraception with mifepristone has been associated with amenorrhea, and patients treated with mifepristone are unable to become pregnant in a short time after discontinuing mifepristone (Lakha et al., 2007).

Some studies have found that mifepristone affects follicle-stimulating hormone (FSH) and luteinizing hormone (LH)-both secreted by the pituitary, subsequently causing a series of reproductive endocrine changes-a side effect likely to contribute to pregnancy failure in females in a short time after discontinuing mifepristone treatment (Tamura et al., 2009; Weisberg et al., 2011).

Reproductive endocrine function in most mammalian species is achieved primarily via the pituitary gonadotrophs, where gonadotropin-releasing hormone (GnRH) binds to GnRH receptors secreted by the hypothalamus to activate-via the three signaling transduction systems, protein kinase C/mitogen-activated protein kinase (PKC-MAPK), Ca2+/calmodulin (Ca2+-CAM), and cyclic adenosine monophosphate/protein kinase A (cAMP-PKA)-the key transcription factors AP-1, Elk-1, Egr-1, Nur77, and CREB, and subsequently regulate the production and secretion of FSH and LH (Escamilla-Hernandez et al., 2008; Kayampilly and Menon, 2008; Caunt et al., 2012). To date, through which of these three mechanisms does mifepristone influence the secretion of FSH and LH remains unclear.

Recently, we treated patients showing infertility after stopping mifepristone with traditional Chinese medicine (TCM) and observed an acceptable therapeutic efficacy. The Bu Shen Zhu Yun formula (BSZYF, Table I) was developed by Professor Guicheng Xia, a renowned TCM gynecologist and "great master in TCM," who developed this empirical formula by modifying Chinese medicinals based on two formulas-one named "Yu Lin Zhu," as reported in the TCM book Jing Yue Quan Shu, and the other named "Yang Jing Zhong Yu Decoction," reported in the TCM book Fu Qing Zhu Nv Ke. This empirical formula has been used for treating LPD-induced infertility and menstrual irregularities for more than 40 years. Our clinical investigations found that this formula exerted effects on gonadotropin levels, ovarian function, and endometrial receptivity in patients with LPD after discontinuing mifepristone. These effects have also been verified in animal experiments.

In this study, we established an LPD animal model with mifepristone, performed intervention experiments with this TCM formula, and observed its effects on pituitary gonadotropin secretion and GnRH receptor signaling transduction systems. Finally, we explained the mechanism underlying mifepristone intervention in pituitary gonadotropin secretion and interpreted the regulating effects of BSZYF.

MATERIALS AND METHODS

Medicines

Mifepristone (Shanghai New Hualian Pharmaceutical Company, Shanghai, China, 25 mg/tablet, Batch No. C019150101) and dydrogesterone tablets (Solvay Pharmaceuticals B.V., Netherlands, 10 mg/tablet, Batch No. 347870) were ground to prepare a uniform suspension with concentrations of 1.0 and 0.4 mg/L, respectively. The medicinals in BSZYF were obtained from TCM granules (Jiangyin Tianjiang Pharmaceutical Company, Jiangsu, China) and mixed according to the combination ratios mentioned (Table I). After mixing, distilled water at 70AdegC was added to generate a suspension with a concentration of 0.08 g (mixed granules)/mL (low-concentration) and 0.24 g (mixed granules)/mL (high-concentration), respectively. All medicines were stored at 4AdegC and allowed to warm to 25-28AdegC before use.

Feeding, grouping, and observation of experimental animals

All the following experimental procedures were performed in accordance with the National Institutes of Health Guidelines for Laboratory Animals, and approved by the Animal Ethics Committee of our institution [No. SYXK (Jiangsu) 2014-0001]. Fifty specific pathogen-free female Sprague-Dawley rats aged 8 weeks and weighing 200 +- 20 g were provided by the Experimental Animal Center, Nanjing University of Traditional Chinese Medicine [SYXK (Beijing) Certificate No. 2012-0001] and fed an SPF diet. The rats were maintained at a temperature of 22-25 AdegC, relative humidity 40-70%, and alternate conditions of light and dark (12h:12h). They had free access to food and water, and were maintained in a quiet environment. Fifty rats were adaptively fed for one week prior to the experiments. At 8:00 a.m. and 4:00 p.m. each day during the adaptive feeding period, vaginal exfoliated cell smears were collected from each rat and observed using an inverted microscope.

The rats were allowed to fully adapt to the capture and smear procedure. Based on the regular patterns observed in the exfoliated cells, it was confirmed that the estrous cycles of all rats were normal (four days) (Caron et al., 2009). The 50 rats were divided into five groups comprising ten rats each, by means of a random number table. The five groups are as follows: Group A (blank), Group B (model),

Group C (dydrogesterone), Group D (low-dose BSZYF), and Group E (high-dose BSZYF). There was no statistically significant difference in body weights among the groups.

Table I.- Composition of Bu Shen Zhu Yun formula.

Pharmaceutical###Botanical or zoological name###Family and part###Chinese name###Weight###Granule weight*

Cervi Cornu###Cervus elaphus Linnaeus###Cervidae; horn###Lu Jiao Pian###10 g###0.5 g; 3 g

Cuscutae Semen###Cuscuta australis R.Br.###Convolvulaceae; seed###Tu Si Zi###15 g###0.5 g; 10 g

Dioscoreae Rhizoma###Dioscorea opposita Thunb.###Dioscoreaceae; rhizome###Shan Yao###15 g###0.5 g; 10 g

Corni Fructus###Cornus officinalis Sieb. et Zucc.###Cornaceae; fruit###Shan Zhu Yu###10 g###1.5 g; 6 g

Paeoniae Radix Alba###Paeonia lactiflora Pall.###Ranunculaceae; root###Chao Bai Shao###10 g###1 g; 10 g

Radix Bupleuri###Bupleurum chinense DC.###Umbelliferae; root###Cu Chai Hu###6g###1 g; 6 g

Animal medication

Vaginal smears were collected for examination at 8:00 a.m. each day. Day 1 (referred to as D1) was identified as the day on which estrum (the early stage of corpus luteum after ovulation) was discerned. All rat groups except Group A were administered mifepristone suspension at a ratio of 1 mL/100 g on D1, D5, and D9 via oral gavage. From the fourth estrous cycle (D13), the rats received different solutions/medicine via oral gavage. Group B received isotonic saline (1 mL/100 g), Group C received dydrogesterone suspension (1 mL/100 g), Group D received low-concentration BSZYF (1 mL/100 g, equivalent to clinical dosage), and Group E received high-concentration BSZYF (1 mL/100 g, equivalent to 3 times the clinical dosage) at four time points (4:00 p.m. on D13, 8:00 a.m. on D14, 4:00 p.m. on D17, and 8:00 a.m. on D18). The blank group received isotonic saline (1 mL/100 g) at the above-mentioned medication time points from D1 to D18 (Zhou et al., 2009; Ghosh and Sengupta, 2014).

Specimen sampling methods

Blood (0.5-1 mL) was collected from the orbital cavity of each group at 4:00 p.m. on D2, D6, D10, and D14 during the treatment period, incubated at a temperature of 22-25 AdegC for 1-2 h, and centrifuged for 15 min at a centrifugation speed of 3000 rpm with a centrifugation radius of 18 cm. The upper layer of serum was collected and stored at -20 AdegC until use. All rats were subjected to intraperitoneal anesthesia with 10% chloral hydrate (0.35 mL/100 g) at 2:00 p.m. on D18. Following anesthesia, blood was collected from the carotid artery, the rats were sacrificed by cervical dislocation, and the pituitary was rapidly removed. The anterior pituitary was isolated on ice, quickly placed in liquid nitrogen, and stored at -80 AdegC until use. Serum was obtained from the collected blood samples as described previously. The feeding, medication, and sampling procedures are illustrated (Fig. 1).

ELISA

A double antibody sandwich ELISA was performed using a kit (Elabscience Biotechnology Co., Ltd., Wuhan, China) to detect FSH and LH in rats. Serum samples were mixed well and diluted to prepare standard samples. The assay was performed in a 96-well plate according to the manufacturer's protocol, and data were collected and analyzed using a multifunction ELISA detection system (TECAN Company, Switzerland).

Real-time PCR

We extracted whole RNA from the rat anterior pituitary tissue using TRIzol lysis solution (Takara Company, Japan) according to the manufacturer's instructions, and synthesized cDNA using a PrimeScriptA(r) RT kit (Takara Company, Japan). Real-time PCR was performed using SYBRA(r) Premix Ex TapTM II kit (Takara Company, Japan) and the primers are listed (Table II). The reaction conditions were as follows: samples were maintained at 95 AdegC for 30 s, and then subjected to 40 cycles of degeneration at 95 AdegC for 5 s and amplification at 60AdegC for 34 s. Each sample was analyzed in triplicate. Data collection and analysis were performed using QuantStudio 7 Flex (Thermo Fisher Scientific Company, USA) and the relative quantization method (IICt). Using HPRT1 as an internal reference parameter, all data were converted for calculation (2-IICt) and statistical analysis.

Western blotting

Rat anterior pituitary tissues were lysed in phenylmethylsulfonyl fluoride (PMSF)-containing RIPA (100 mg/mL; Boster Company, Wuhan, China) and centrifuged at a speed of 12,000 rpm with a radius of 18 cm for 30 min at 4AdegC. Protein content was determined using a bicinchoninic acid (BCA) protein concentration kit (Thermo Fisher Scientific Company, USA) and the samples were denatured in 2X electrophoresis buffer (BioRad Company, USA) at 100 AdegC for 5 min, followed by storage at -80 AdegC. Total proteins were isolated using 8-12% SDS-PAGE in a vertical electrophoresis apparatus, transferred to semi-dry polyvinylidene fluoride (PVDF) membrane (Millipore, USA), blocked with 5% bovine serum albumin (BSA) solution [with tris-buffered saline (TBS) Tween 20, TBST, 25 mM Tris [pH 7.5], 150 mM NaCl and 0.1% Tween 20] for 2 h.

The membranes were incubated with primary antibodies, including GnRHR, c-Jun, Elk-1, Egr-1, Nur77, CREB, PKC, ERK1/2, p38MAPK, JNK1/2, PKA, CAM, and tubulin (Abcam Ltd., USA) overnight at 4 AdegC. Goat anti-rabbit horseradish peroxidase-conjugated IgG (Cell Signaling Technology Inc., USA) was used to detect antibody binding. A ChemiDOCTM MP (BioRad Company, USA) western blot multifunction imaging system was used to develop blot images, and image data were collected and analyzed using ImageLab software (BioRad Company, USA).

Statistical analysis

Statistical analysis was conducted using Prism 6.0 software (GraphPad Software, San Diego, CA, USA). All quantitative data were subjected to a normal distribution test. Data conforming to a normal distribution were presented as mean +- standard deviation (X +- SD), and one-way ANOVA was used to compare the means among different groups of data that conformed to homogeneity of variances. A least significant difference test was used for paired comparison. The Dunnett T3 method was used for analysis of data not conforming to homogeneity of variances. Data not following a normal distribution were expressed as interquartile ranges, and a non-parametric test (Kruskal-Wallis) was employed for data analysis. Values of P<0.05 were deemed statistically significant.

Table II.- Real-time PCR primer sequences.

Gene###Forward Primer (5-3)###Reverse Primer (5-3)###Product (bp)

FSH###GGACCCAGCTAGACCAAACA###ACAGTGGCATTCAGTGGCTA###133

LH###CTGAGCCCAAGTGTGGTGT###ATGCTGGTGGTGAAGGTGAT###122

GnRHR###GTGGTGATTAGCCTGGATCG###ATAACTGTGGTCCCGCAAAG###130

c-Jun###TGACTGCAAAGATGGAAACG###CCAGGTTCAAGGTCATGCTC###126

Elk-1###TCCACCTCCACCACTGAGAT###CCAGAGCTTGTTCCTGATCC###131

Egr-1###AACACTTTGTGGCCTGAACC###AGGCAGAGGAAGACGATGAA###118

Nur77###GGCATGGTGAAGGAAGTTGT###GAATGAGGGACGTGAGGAGA###118

CREB###GATTCTAGTGCCCAGCAACC###GGAGGACGCCATAACAACTC###118

PKC###AATGGCCTGTCTGATCCCTA###ACACGAAGGTCTCGTTCCAC###121

ERK1###CTCTCCAACCGGCCTATCTT###AGGTAGTTTCGGGCCTTCAT###128

ERK2###CCTACGGCATGGTTTGTTCT###TCTCATGTCTGAAGCGCAGT###141

P38mapk###GGCACACTGATGACGAAATG###CCACGGACCAAATATCCACT###111

Jnk###ATGATGACGCCTTACGTGGT###GGCAAACCATTTCTCCCATA###121

CAM###GCACCATTGACTTCCCAGAG###GATGTAGCCATTGCCATCCT###119

PKA###TACCTCCATTCCCTCGACCT###CCTTGACTCTCTTGGCGAAC###112

HPRT1###AGCAGACGTTCTAGTCCTGTG###GGCTGCCTACAGGCTCATAG###136

RESULTS

BSZYF improved suppression of FSH secretion induced by mifepristone

ELISA results obtained in serum collected at 5 different times showed that mifepristone effectively suppressed the secretion of FSH from the start of treatment to two weeks after the end of treatment. All differences were statistically significant. Following BSZYF treatment, the FSH levels recovered rapidly. At D14 and D18, there was no statistically significant difference in FSH levels between the BSZYF groups and the blank group. The BSZYF groups showed better efficacy to recover the FSH levels than the dydrogesterone group. Consistent with the FSH level results, the BSZYF group improved the suppression of FSH[beta] mRNA expression induced by mifepristone in the anterior pituitary tissue samples. However, both mifepristone and BSZYF groups did not show a significant effect on LH secretion, and there was no statistically significant difference in LH[beta] mRNA levels between the groups (Fig. 2).

BSZYF increased GnRH receptor expression following its suppression by mifepristone

GnRH receptors in the anterior pituitary gonadotrophs are the primary regulation nodes for the secretion of FSH and LH. GnRH binds to GnRH receptor resulting in the synthesis and release of FSH and LH (Yu et al., 2011). The expression levels of GnRH receptor in the rat anterior pituitary following mifepristone intervention for three estrous cycles and two estrous cycles post-intervention were significantly lower than those in the blank group, indicating that mifepristone might influence the secretion of FSH and LH by reducing GnRH receptor activity in the pituitary. However, GnRH expression levels in Groups D and E increased to some extent, indicating that BSZYF may be involved in regulating gonadotropin levels (Fig. 3).

Effect of mifepristone and BSZYF on the expression of key transcription factors in the rat anterior pituitary tissues

Among the signal transduction pathways in pituitary gonadotrophs, the PKC-MAPK pathway primarily activates c-Jun, Elk-1, and Egr-1, and the cAMP-PKA pathway primarily activates CREB and Egr-1, while the Ca2+-mediated signaling pathway primarily activates Nur77, c-Jun, and Egr-1 (Naor et al., 1997; Melamed et al., 2012; Thompson et al., 2013). Mifepristone significantly decreased both mRNA and protein expression of c-Jun, Egr-1, Elk-1, and CREB in the rat anterior pituitary tissues but did not influence the expression of Nur77. BSZYF treatment increased the mRNA and protein expression of c-Jun, Elk-1, Egr-1 and CREB, which had decreased following mifepristone treatment; however, the expression of c-Jun, Elk-1, Egr-1, and CREB was not significantly different from that in the blank group (Fig. 4).

Effect of mifepristone and BSZYF on the expression of nodal molecules in the signaling pathways

PKC in PKC-MAPK is a pivotal node in post-GnRH receptor signaling pathways, mediating a cascade amplification of MAPK, and it includes three branches: ERK, p38MAPK, and JNK (Sharma et al., 2013). PKA and CAM are pivotal nodes in the cAMP-PKA and Ca2+-CAM signaling pathways. Mifepristone significantly suppressed both mRNA and protein expression of PKC, ERK1/2, p38MAPK, JNK, and PKA in PKC-MAPK signaling pathway, while there was no significant change in the expression of CAM. BSZYF increased the expression of PKC, ERK1/2, p38MAPK, JNK, and PKA, which was suppressed by mifepristone treatment; however, the differences were not significant compared with the blank group (Fig. 5).

DISCUSSION

Based on the experimental results, we were able to draw some preliminary conclusions. First, after ovulation, mifepristone decreased the secretion levels of gonadotropin at the late stage of the rat estrous cycle (similar to the human luteal phase (McClintock, 1983)), and the secretion levels do not automatically recover for at least two estrous cycles after discontinuing mifepristone treatment. This effect may be attributed to the suppression of GnRH receptor expression in the pituitary and downstream transcription factor c-Jun, Egr-1, Elk-1, and CREB expression in PKC-MAPK and cAMP-PKA signaling transduction pathways by mifepristone. Second, BSZYF effectively restores GnRH receptor expression in the rat anterior pituitary and post-receptor signaling transduction systems suppressed by mifepristone, and increases FSH secretion levels back to the normal level of the blank group.

Finally, mifepristone and BSZYF did not have a significant effect on the expression of CAM or downstream Nur77 in the Ca2+-CAM signaling pathway, indicating that these medications do not affect Ca2+ binding to CAM under normal conditions.

Mifepristone acts as a competitive antagonist of progesterone, blocking its binding to the progesterone receptor. It has a four- or five-fold greater affinity for the progesterone receptor than progesterone (Bouchard et al., 2011), thereby significantly suppressing the normal biological effects of progesterone as well as the function of corpus luteum. Pharmacokinetic studies have shown that a one-time oral administration of 100 mg mifepristone at the non-pregnant luteal phase leads to a peak plasma-drug concentration within 1 h, with an elimination half-life of 12-24 h. Therefore, a 100-800 mg dose would not cause a significant change in plasma-drug concentration and would less likely result in the accumulation of the drug in the blood (Sarkar, 2005). However, until recently, the adverse effects of mifepristone on reproductive endocrine function have received little attention and remain insufficiently studied.

Some studies have shown that in normal conditions, the ratio between FSH and LH in the luteal metaphase is relatively stable. If the ratio of LH:FSH is too high, it can lead to early atrophy of the corpus luteum and affect the normal development of the ovarian follicle in the next menstrual cycle, which in turn imposes further adverse effects on the function of corpus luteum (Cook et al., 1983). Moreover, mifepristone can disturb the normal secretion of inhibin (Spitz, 2003) and testosterone (Wu et al., 2014), aggravate the ratio imbalance of LH/FSH, and cause LPD or even infertility after the medication is discontinued.

Pituitary gonadotropin secretion is not only regulated by GnRH secreted by the hypothalamus, but is also associated with the signal transduction of the GnRH receptor. GnRHR is expressed in the anterior pituitary (Mertani et al., 1996) and is a member of the rhodopsin-like G-protein coupled receptor family (Naor and Huhtaniemi, 2013). Following GnRH binding to GnRHR in the pituitary, GnRH enables signaling transduction via a variety of G-protein coupled signaling pathways and ultimately affects the secretion of FSH and LH (Naor et al., 1998; Oh et al., 2003; Melamed et al., 2012). In normal conditions, an intervention of PKA and PKC in the cAMP-PKA and PKC-MAPK signaling pathways of pituitary GTH cells affect gene expression and secretion levels of FSH and LH in the pituitary, implying that the transduction functions of these two signaling pathways are pivotal factors influencing the secretion of FSH and LH in the pituitary (Naor et al., 1998; Garrido-Gracia et al., 2006; Zhao et al., 2011).

CREB, a key protein that regulates gene transcription function, contains multiple activation sites that can be activated by a number of protein kinases including PKA, and it is one of the key nodes in the signaling transduction pathway of cAMP-PKA (Kasper et al., 2010). CREB can also be activated by the influx of Ca2+. It can competitively bind to the AP-1 site in the MAPK signaling transduction pathway and reduce the production of c-Jun subunit of AP-1 (Cheng and Leung, 2001), thereby suppressing MAPK signaling transduction and affecting PKC-MAPK signaling pathway. In this study, both CREB and AP-1 were suppressed by mifepristone, but their expression levels returned to normal levels following BSZYF treatment and no competitive effect was observed. We suggest that the decreased expression levels of CREB following suppression of the cAMP-PKA signaling pathway also suppressed the PKC-MAPK signaling pathway, which plays a pivotal role in AP-1 expression, thereby decreasing the expression of AP-1.

Similarly, after the suppression of cAMP-PKA and PKC-MAPK signaling pathways was ameliorated, the expression of CREB and AP-1 increased significantly. However, in this study, we found that although mifepristone affected the expression of PKA and PKC as well as a series of downstream key nodes, the levels of LH did not change significantly when FSH secretion decreased. It is unclear whether this observation was attributed to the signaling transduction pathway of Ca2+-CAM or other underlying mechanisms. Therefore, more research is required to address this issue.

When administered in the premenstrual period (after ovulation), BSZYF can tonify the kidney yang, move the Qi in heart and liver, and tranquilize the heart and liver. Clinical research and previous studies have also shown that this formula can improve ovarian cell function and endometrial receptivity, regulate menstrual function, and promote pregnancy (Zhou et al., 2009). Given the difference in the theoretical system and the expression approach between Western medicine and TCM, the "hypothalamus-pituitary-ovary reproduction axis" (H-P-O axis) in Western medicines does not exactly correspond to the "heart (brain)-kidney-uterus reproduction axis' in TCM, although both axes represent the same basic process. Mifepristone not only has an antagonistic effect on progesterone in the endometrium, but can also cause the dysfunction of reproduction axis.

Although it is unlikely to lead to severe menstrual disorders, mifepristone withdrawal is likely to result in a certain degree of dysfunction and LPD-like presentation (Lakha et al., 2007; Sun et al., 2014). Following BSZYF administration, the secretory function in the pituitary, which is at the center of the reproduction axis, is likely to recover.

CONCLUSION

Based on our experimental results, we speculate that the modulation of corpus luteal function by BSZYF not only affects the uterus and ovaries, which are downstream of the reproduction axis, but also regulates gonadotropin secretion in the pituitary, which is in the center of the reproduction axis.

ACKNOWLEDGMENT

The research was supported by China and Europe Taking Care of Healthcare Solutions (CHETCH), a project of the Marie Curie Actions, (Nos. FP7/2007-2013/PIRSES-GA-2013-612589), the Natural Science Foundation of China (Nos. 81473713), and the Natural Science Project of Jiangsu Province, China (BK20141463).

Statement of conflict of interest

We declare no conflicts of interest in this study.

REFERENCES

Boggavarapu, N.R., Berger, C., von Grothusen, C., Menezes, J., Gemzell-Danielsson, K. and Lalitkumar, P.G., 2016. Effects of low doses of mifepristone on human embryo implantation process in a three-dimensional human endometrial in vitro co-culture system. Contraception, 94: 143-151. https://doi.org/10.1016/j.contraception.2016.03.009

Bouchard, P., Chabbert-Buffet, N. and Fauser, B.C., 2011. Selective progesterone receptor modulators in reproductive medicine: Pharmacology, clinical efficacy and safety. Fertil. Steril., 96: 1175-1189. https://doi.org/10.1016/j.fertnstert.2011.08.021

Cameron, S.T., Critchley, H.O., Thong, K.J., Buckley, C.H., Williams, A.R. and Baird, D.T., 1996. Effects of daily low dose mifepristone on endometrial maturation and proliferation. Hum. Reprod., 11: 2518-2526. https://doi.org/10.1093/oxfordjournals.humrep.a019151

Caron, PL, Frechette-Frigon, G., Shooner, C., Leblanc, V. and Asselin, E., 2009. Transforming growth factor beta isoforms regulation of Akt activity and XIAP levels in rat endometrium during estrous cycle, in a model of pseudo-pregnancy and in cultured decidual cells. Reprod. Biol. Endocrinol., 7: 80. https://doi.org/10.1186/1477-7827-7-80

Caunt, C.J., Perett, R.M., Fowkes, R.C. and McArdle, C.A., 2012. Mechanisms of GnRH-induced extracellular signal-regulated kinase nuclear localization. PLoS One, 7: e40077. https://doi.org/10.1371/journal.pone.0040077

Cheng, K.W. and Leung, P.C., 2001. Human gonadotropin-releasing hormone receptor gene transcription: Up-regulation by 3',5'-cyclic adenosine monophosphate/protein kinase A pathway. Mol. Cell. Endocrinol., 181: 15-26. https://doi.org/10.1016/S0303-7207(01)00480-4

Cook, C.L., Rao, C.V. and Yussman, M.A., 1983. Plasma gonadotropin and sex steroid hormone levels during early, midfollicular, and midluteal phases of women with luteal phase defects. Fertil. Steril., 40: 45-48. https://doi.org/10.1016/S0015-0282(16)47175-X

Escamilla-Hernandez, R., Little-Ihrig, L., Orwig, K.E., Yue, J., Chandran, U. and Zeleznik, A.J., 2008. Constitutively active protein kinase A qualitatively mimics the effects of follicle-stimulating hormone on granulosa cell differentiation. Mol. Endocrinol., 22: 1842-1852. https://doi.org/10.1210/me.2008-0103

Garrido-Gracia, J.C., Bellido, C., Aguilar, R. and Sanchez-Criado, J.E., 2006. Protein kinase C cross-talk with gonadotrope progesterone receptor is involved in GnRH-induced LH secretion. J. Physiol. Biochem, 62: 35-42. https://doi.org/10.1007/BF03165804

Ghosh, D. and Sengupta, J., 2014. Delineating the prime mover action of progesterone for endometrial receptivity in primates. Indian J. med. Res., 140(Suppl): S130-S136.

Kasper, LH, Lerach, S., Wang, J., Wu, S., Jeevan, T. and Brindle, P.K., 2010. CBP/p300 double null cells reveal effect of coactivator level and diversity on CREB transactivation. EMBO J., 29: 3660-3672. https://doi.org/10.1038/emboj.2010.235

Kayampilly, P.P. and Menon, K.M., 2009. Follicle-stimulating hormone inhibits adenosine 5'-monophosphate-activated protein kinase activation and promotes cell proliferation of primary granulosa cells in culture through an Akt-dependent pathway. Endocrinology, 150: 929-935. https://doi.org/10.1210/en.2008-1032

Lakha, F., Ho, P.C., van der Spuy, Z.M., Dada, K., Elton, R. and Glasier, A.F., 2007. A novel estrogen-free oral contraceptive pill for women: Multicentre, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel). Hum. Reprod., 22: 2428-2436. https://doi.org/10.1093/humrep/dem177

McClintock, M.K., 1983. Modulation of the estrous cycle by pheromones from pregnant and lactating rats. Biol. Reprod., 28: 823-829. https://doi.org/10.1095/biolreprod28.4.823

Melamed, P., Savulescu, D., Lim, S., Wijeweera, A., Luo, Z. and Luo, M., 2012. Gonadotrophin-releasing hormone signalling downstream of calmodulin. J. Neuroendocrinol., 24: 1463-1475. https://doi.org/10.1111/j.1365-2826.2012.02359.x

Mertani, H.C., Testart, C., Ouhtit, A., Brisson, C. and Morel, G., 1996. Gonadotropin-releasing hormone receptor gene expression in rat anterior pituitary. Endocrine, 4: 159-163. https://doi.org/10.1007/BF02782760

Naor, Z. and Huhtaniemi, I., 2013. Interactions of the GnRH receptor with heterotrimeric G proteins. Front. Neuroendocrin., 34: 88-94. https://doi.org/10.1016/j.yfrne.2012.11.001

Naor, Z, Harris, D. and Shacham, S., 1998. Mechanism of GnRH receptor signaling: Combinatorial cross-talk of Ca2+ and protein kinase C. Front. Neuroendocrin., 19: 1-19. https://doi.org/10.1006/frne.1997.0162

Oh, D.Y., Wang, L., Ahn, R.S., Park, J.Y., Seong, J.Y. and Kwon, H.B., 2003. Differential G protein coupling preference of mammalian and nonmammalian gonadotropin-releasing hormone receptors. Mol. Cell Endocrinol., 205: 89-98. https://doi.org/10.1016/S0303-7207(03)00204-1

Sarkar, N.N., 2005. The potential of mifepristone (RU-486) as an emergency contraceptive drug. Acta Obstet. Gyn. Scand., 84: 309-316. https://doi.org/10.1111/j.0001-6349.2005.00418.x

Sharma, S., Morinaga, H., Hwang, V., Fan, W., Fernandez, M.O. and Varki, N., 2013. Free fatty acids induce Lhb mRNA but suppress Fshb mRNA in pituitary L[beta]T2 gonadotropes and diet-induced obesity reduces FSH levels in male mice and disrupts the proestrous LH/FSH surge in female mice. Endocrinology, 154: 2188-2199. https://doi.org/10.1210/en.2012-2218

Spitz, I.M., 2003. Progesterone antagonists and progesterone receptor modulators: An overview. Steroids, 68: 981-993. https://doi.org/10.1016/j.steroids.2003.08.007

Sun, Y., Fang, M., Davies, H. and Hu, Z., 2014. Mifepristone: A potential clinical agent based on its anti-progesterone and anti-glucocorticoid properties. Gynecol. Endocrinol., 30: 169-173. https://doi.org/10.3109/09513590.2013.856410

Tamura, T., Yokoi, R., Okuhara, Y., Harada, C., Terashima, Y. and Hayashi, M., 2009. Collaborative work on evaluation of ovarian toxicity. 2) Two- or four-week repeated dose studies and fertility study of mifepristone in female rats. J. toxicol. Sci., 34: SP31-42. https://doi.org/10.2131/jts.34.S31

Thompson, I.R., Ciccone, N.A., Xu, S., Zaytseva, S., Carroll, R.S. and Kaiser, U.B., 2013. GnRH pulse frequency-dependent stimulation of FSH[beta] transcription is mediated via activation of PKA and CREB. Mol. Endocrinol., 27: 606-618. https://doi.org/10.1210/me.2012-1281

Weisberg, E., Croxatto, H.B., Findlay, J.K., Burger, H.G. and Fraser, I.S., 2011. A randomized study of the effect of mifepristone alone or in conjunction with ethinyl estradiol on ovarian function in women using the etonogestrel-releasing subdermal implant, ImplanonA(r). Contraception, 84: 600-608. https://doi.org/10.1016/j.contraception.2011.04.008

Wu, S, Chen, Y., Fajobi, T., DiVall, S.A., Chang, C. and Yeh, S., 2014. Conditional knockout of the androgen receptor in gonadotropes reveals crucial roles for androgen in gonadotropin synthesis and surge in female mice. Mol. Endocrinol., 28: 1670-1681. https://doi.org/10.1210/me.2014-1154

Yu, B., Ruman, J. and Christman, G., 2011. The role of peripheral gonadotropin-releasing hormone receptors in female reproduction. Fertil. Steril., 95: 465-473. https://doi.org/10.1016/j.fertnstert.2010.08.045

Zhao, E., McNeilly, J.R., McNeilly, A.S., Fischer-Colbrie, R., Basak, A., and Seong, J.Y., 2011. Secretoneurin stimulates the production and release of luteinizing hormone in mouse L[beta]T2 gonadotropin cells. Am. J. Physiol. Endocrinol. Metab., 301: E288-297. https://doi.org/10.1152/ajpendo.00070.2011

Zhou, H.F., Li, A.P. and Tan, Y., 2009. Effects of bushen zhuyun recipe on protein expressions of estrogen receptor, progesterone receptor and integrin alpha5 and beta3 in endometrium of rats at the implantation stage. Zhongguo Zhong Xi Yi Jie He Za Zhi, 29: 628-631.
COPYRIGHT 2019 Knowledge Bylanes
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Li, Zhen-li; Zhou, Hui-fang; Liu, Bei; Zhou, Bo-ru; Jiang, Xiao-fei; Xu, Jian-ya
Publication:Pakistan Journal of Zoology
Article Type:Report
Date:Apr 30, 2019
Words:5050
Previous Article:Effectiveness of Nuclear Polyhedrosis Virus and Bacillus thuringiensis alone and in Combination against Spodoptera litura (Fabricius).
Next Article:The Effect of Hemodialysis on the Expression of CXCL8 and its mRNA in Neutrophils of the Patients with Chronic Renal Failure.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters